Ignite Creation Date:
2024-05-05 @ 7:39 PM
Last Modification Date:
2024-10-26 @ 9:51 AM
Study NCT ID:
NCT00710372
Status:
COMPLETED
Last Update Posted:
2010-11-15
First Post:
2008-07-03
Brief Title:
Safety Tolerability and Efficacy of a Vaccine Against Essential Hypertension
Sponsor:
Cytos Biotechnology AG
Organization:
Cytos Biotechnology AG
Study Overview
Official Title:
A Double Blind Randomized Placebo Controlled Parallel Group Dose-Titration Phase II Study to Evaluate Safety and Tolerability Pharmacodynamic Effects and Efficacy of an Anti-Angiotensin II Vaccine CYT006-AngQb in Patients With Mild to Moderate Essential Hypertension
Status:
COMPLETED
Status Verified Date:
2010-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study medication CYT006-AngQb is a vaccine consisting of angiotensin II Ang II the naturally occurring octapeptide coupled onto the surface of virus-like particles VLP This form of presenting Ang II to the immune system induces a B-cell mediated immune response characterized by the generation of specific antibodies IgG and IgM against Ang II The CYT006-AngQb vaccine is administered by subcutaneous sc injection Immunization against angiotensin II may offer a valuable alternative to conventional drugs for the treatment of hypertension
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EudraCT No 2007-007516-28 | None | None | None |